For most of its life, Rigel Pharmaceuticals was a company that spent more than it earned. From 2021 through 2023, it lost money every year, sometimes badly. Then something shifted: the fiscal year 2025 annual filing showed revenue of $294 million and a net margin, meaning what the company kept after every bill, of nearly 125%. That is not a rounding error. It is the number sitting at the center of every question a careful reader should ask right now.
The story, briefly
The filed numbers show a company that turned profitable in FY2024 and then accelerated sharply in FY2025, before spending a large chunk of its cash reserves on a newly licensed drug. The stock has risen sharply over the past year and now sits near its fifty-two-week high, meaning the mood, what the market is currently paying, has already priced in a great deal of optimism. The math, what the underlying filings actually justify, depends almost entirely on whether that licensed drug earns back its cost. That gap between a confident price and an unproven new product is the story.
How Rigel Got Here
The turnaround rests on two commercial drugs. Fostamatinib, sold as TAVALISSE for a rare blood-platelet disorder, has been grinding out steady growth for years. Pralsetinib, sold as GAVRETO for certain lung and thyroid cancers, added a second revenue stream. By the time the 2025 annual report was filed, those two products together pushed revenue past $290 million, more than double what the company earned two years earlier. That is the backstory: a small pharmaceutical company that spent years losing money on a single approved drug finally reached the scale where the fixed costs of running a commercial operation stopped eating all the profit.
TAVALISSE net product sales grew by nearly a fifth in the most recent quarter compared with the same period a year earlier, according to the Q2 2026 earnings release. That is the engine. Everything else is a question about what gets bolted onto it.
What Changed in the Quarter
The 10-Q for the quarter ended June 30, 2026 filed August 4 shows two moves happening at once, and they pull in opposite directions.
First, Rigel added something. The company in-licensed VEPPANU (vepdegestrant), an FDA-approved drug for advanced breast cancer, paying $70 million upfront. VEPPANU belongs to a class called PROTACs, a mechanism that tags disease-causing proteins for destruction inside the cell rather than simply blocking them. Think of it as calling in a disposal crew rather than putting a lock on a door. U.S. commercial availability was expected in mid-August 2026. The $70 million payment is real and already spent; the revenue is not yet in the numbers.
Second, Rigel lost something. Eli Lilly terminated its collaboration on ocadusertib, a drug for inflammatory diseases, effective June 15, 2026, according to the same Q2 earnings release. A partner walking away from a collaboration is rarely good news, and the pipeline is thinner for it.
The net result: Rigel ended June with $95.3 million in cash and short-term investments, after absorbing that $70 million outlay. That cushion is meaningful but not enormous for a company now carrying three commercial products and an active clinical program.
What Compounds
One clinical asset remains: R289, a dual IRAK1/4 inhibitor, meaning it blocks two related proteins involved in inflammation, currently in a Phase 1b study for lower-risk myelodysplastic syndrome, a bone marrow condition that impairs blood cell production. R289 holds FDA Fast Track and Orphan Drug designations, both of which can accelerate the review process. Dose expansion enrollment was on track to complete in the second half of 2026, with preliminary data expected by year-end, per the Q2 release. Phase 1b is early, meaning years and significant spending stand between today and any potential approval.
Meanwhile, a reading of the 10-K, FY2025 suggests Rigel’s approach centers on identifying and commercializing drugs that larger companies have deprioritized, leveraging its existing sales infrastructure. VEPPANU fits that pattern: it was developed elsewhere, approved by the FDA, and handed to Rigel to sell. The thesis is that a commercial machine already built to sell two drugs can add a third without proportionally adding cost. Whether that holds depends on how quickly VEPPANU finds patients.
Reading the Numbers
- $78.7 million, Q2 2026 total revenues (10-Q, June 30, 2026): What it is: the company’s total sales for one quarter. What it means here: annualized, that pace would approach $315 million, ahead of the full-year 2025 total. In everyday terms, imagine a shop that used to take in $100 a week now taking in roughly $270 in a single week. The growth is real, but the next question is whether it holds.
- $17.3 million, Q2 2026 net income (10-Q, June 30, 2026): What it is: what the company kept after all expenses. What it means here: for a business that lost money as recently as 2023, posting profit in back-to-back quarters is a structural shift, not a one-time item. A household that spent years running a deficit and then banked two months of surplus in a row has genuinely changed something.
- P/E of 2.6 vs. a decade median of 20.7 (calculated from SEC EDGAR annual filings FY2015–FY2025; see filings index): What it is: the price-to-earnings ratio, meaning the price tag per dollar of annual profit. What it means here: the ratio sits below its own historical range, though the decade median includes years when Rigel had no earnings at all, which limits the comparability of the figure. A business that earned almost nothing for most of a decade and then earned a lot in one unusual year is not straightforwardly valued at any simple multiple of that year’s profit.
- $95.3 million cash after a $70 million payment (10-Q, June 30, 2026): What it is: the remaining liquidity after the VEPPANU deal closed. What it means here: a family that had roughly $165,000 in savings, wrote a $70,000 check, and now has $95,000 left. That is still meaningful, but it leaves less room for the next unexpected expense, whether a clinical setback or a slower-than-expected product launch.
Reading the numbers
Three figures carry most of the weight in this article.
$294 million in full-year 2025 revenue, with a net margin of nearly 125%. Revenue is simply the total money customers paid the company. A net margin above 100% sounds impossible, but it can happen when a company receives large one-time payments, such as milestone fees from partners, that are counted as income but do not show up as product sales. What matters here is that this number marks the acceleration of Rigel’s profitability, which began in FY2024 and expanded dramatically in FY2025. It is the clearest signal that the turnaround has taken hold. Without it, the $70 million bet on VEPPANU would look reckless; with it, the company at least had a foundation to spend from.
$70 million upfront for VEPPANU. This is the single largest decision in the recent filing. Rigel wrote a check for $70 million to license a drug that has FDA approval but has not yet generated a dollar of revenue for Rigel. That payment is already gone. The company now needs VEPPANU to sell well enough to earn that money back, and then some, before the investment makes sense. Think of it as buying a franchise location: the fee is paid on day one, but the profit depends entirely on how many customers walk through the door over the following years. The story turns on whether those customers show up.
$95.3 million in cash remaining after the deal. This is what Rigel has left to operate on. Before the VEPPANU payment, the company held roughly $165 million. After writing that check, $95.3 million remained. That number matters because it sets the clock: if VEPPANU launches slowly, or if R289 clinical costs rise, or if any other expense surprises, this is the buffer standing between the company and a need to raise more money, which typically means selling new shares and diluting the shareholder base. A larger cushion would mean more time to let the new drug find its footing. A smaller one means less margin for error.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- Rigel Q2 2026 earnings press release
- Seeking Alpha: Rigel Pharmaceuticals, turning big pharma’s castoffs into a growth engine (third-party opinion)
- Rigel 2026 business update and outlook
- Rigel Q4 and full-year 2025 financial results
